Oxidized Low-Density Lipoprotein Biomarkers in Patients with End-Stage Renal Failure: Acute Effects of Hemodialysis
Objective: To assess the effect of end-stage renal failure on oxidized low-density lipoprotein (OxLDL) biomarkers and the acute effects of hemodialysis. Oxidized phospholipids (OxPL) on apolipoprotein B-100 (apoB) particles (OxPL/apoB) have been associated with cardiovascular disease and new cardiov...
Gespeichert in:
Veröffentlicht in: | Blood purification 2007-01, Vol.25 (5-6), p.457-465 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 465 |
---|---|
container_issue | 5-6 |
container_start_page | 457 |
container_title | Blood purification |
container_volume | 25 |
creator | Bossola, Maurizio Tazza, Luigi Merki, Esther Giungi, Stefania Luciani, Giovanna Miller, Elizabeth R. Lin, Edward B. Tortorelli, Antonio Tsimikas, Sotirios |
description | Objective: To assess the effect of end-stage renal failure on oxidized low-density lipoprotein (OxLDL) biomarkers and the acute effects of hemodialysis. Oxidized phospholipids (OxPL) on apolipoprotein B-100 (apoB) particles (OxPL/apoB) have been associated with cardiovascular disease and new cardiovascular events. Patients with end-stage renal failure have increased oxidative stress and are at significantly increased risk of cardiovascular disease. Methods and Results: Fifty-two stable patients with end-stage renal failure undergoing chronic hemodialysis were included in the study. Pre and post hemodialysis blood samples were obtained for measurement of OxLDL biomarkers: oxidized phospholipids (OxPL) on apolipoprotein B-100 (apoB) particles (OxPL/apoB) measured by antibody E06, IgG and IgM autoantibody titers to copper-oxidized LDL (Cu-OxLDL) and malondialdehyde (MDA)-LDL, IgG and IgM apolipoprotein B-100-immune complexes (IC/apoB). Traditional laboratory variables as well as C-reactive protein (CRP) and lipoprotein(a) [Lp(a)] were also measured. For the baseline variables, the distribution of OxPL/apoB and Lp(a) were skewed to lower values, and a strong correlation was noted between OxPL/apoB and Lp(a) (r = 0.94, p < 0.0001). No major associations were noted between OxLDL biomarkers and age, gender or dialytic age. There were also no correlations between OxLDL biomarkers and traditional risk factors, CRP, body mass index, serum creatinine, hypertension or intravenous iron therapy. Following dialysis, there as a significant reduction in OxPL/apoB (–7.5%, p = 0.048) and triglyceride levels (–10.8%, p = 0.005). All other OxLDL biomarkers, CRP, total cholesterol, LDL-C, HDL-C and apoB-100 increased significantly (range 6.3–26.9%, p value range 0.005 to |
doi_str_mv | 10.1159/000112465 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000112465</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70083483</sourcerecordid><originalsourceid>FETCH-LOGICAL-c334t-99e6db71cf297a4e76c3d959dbec48d0962e2eadbcbafe9d40ee542cc043005f3</originalsourceid><addsrcrecordid>eNpF0MtrGzEQBnBRUmon7SH3EHRpIIdN9Nxd5ZaH0wQMLn2cF600StWsd11JS-L-9ZGxcU7DwI9vmA-hY0ouKJXqkhBCKROl_ICmVDBaqIrLAzQlTPJCkrKeoMMY_2aVjfqEJrQmlWSimqK4ePXW_weL58NLcQd99GmN5341rMKQwPf4xg9LHZ4hRJy37zp56FPELz79wbPeFj-TfgL8A3rd4XvtuzHAFb42YwI8cw5MtoPDD7AcrNfdOvr4GX10uovwZTeP0O_72a_bh2K--PZ4ez0vDOciFUpBaduKGsdUpQVUpeFWSWVbMKK2RJUMGGjbmlY7UFYQACmYMURwQqTjR-hsm5tf-TdCTM3SRwNdp3sYxthUhNRc1DzD8y00YYgxgGtWween1w0lzabhZt9wtqe70LFdgn2Xu0oz-LoDOhrduaB74-PesZxE6nJz9GTrnnV4gvAetL3zBnuLjSg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70083483</pqid></control><display><type>article</type><title>Oxidized Low-Density Lipoprotein Biomarkers in Patients with End-Stage Renal Failure: Acute Effects of Hemodialysis</title><source>MEDLINE</source><source>Karger Journals Complete</source><creator>Bossola, Maurizio ; Tazza, Luigi ; Merki, Esther ; Giungi, Stefania ; Luciani, Giovanna ; Miller, Elizabeth R. ; Lin, Edward B. ; Tortorelli, Antonio ; Tsimikas, Sotirios</creator><creatorcontrib>Bossola, Maurizio ; Tazza, Luigi ; Merki, Esther ; Giungi, Stefania ; Luciani, Giovanna ; Miller, Elizabeth R. ; Lin, Edward B. ; Tortorelli, Antonio ; Tsimikas, Sotirios</creatorcontrib><description>Objective: To assess the effect of end-stage renal failure on oxidized low-density lipoprotein (OxLDL) biomarkers and the acute effects of hemodialysis. Oxidized phospholipids (OxPL) on apolipoprotein B-100 (apoB) particles (OxPL/apoB) have been associated with cardiovascular disease and new cardiovascular events. Patients with end-stage renal failure have increased oxidative stress and are at significantly increased risk of cardiovascular disease. Methods and Results: Fifty-two stable patients with end-stage renal failure undergoing chronic hemodialysis were included in the study. Pre and post hemodialysis blood samples were obtained for measurement of OxLDL biomarkers: oxidized phospholipids (OxPL) on apolipoprotein B-100 (apoB) particles (OxPL/apoB) measured by antibody E06, IgG and IgM autoantibody titers to copper-oxidized LDL (Cu-OxLDL) and malondialdehyde (MDA)-LDL, IgG and IgM apolipoprotein B-100-immune complexes (IC/apoB). Traditional laboratory variables as well as C-reactive protein (CRP) and lipoprotein(a) [Lp(a)] were also measured. For the baseline variables, the distribution of OxPL/apoB and Lp(a) were skewed to lower values, and a strong correlation was noted between OxPL/apoB and Lp(a) (r = 0.94, p < 0.0001). No major associations were noted between OxLDL biomarkers and age, gender or dialytic age. There were also no correlations between OxLDL biomarkers and traditional risk factors, CRP, body mass index, serum creatinine, hypertension or intravenous iron therapy. Following dialysis, there as a significant reduction in OxPL/apoB (–7.5%, p = 0.048) and triglyceride levels (–10.8%, p = 0.005). All other OxLDL biomarkers, CRP, total cholesterol, LDL-C, HDL-C and apoB-100 increased significantly (range 6.3–26.9%, p value range 0.005 to <0.0001). Total protein plasma levels increased 8.8% (p = 0.014 compared to predialysis) following dialysis, consistent with a hemoconcentration effect of hemodialysis. Conclusion: In end-stage renal failure patients undergoing hemodialysis, a reduction in OxPL/apoB levels was noted, despite the hemoconcentrating and strong pro-oxidant milieu of hemodialysis. Studies in larger populations of end-stage renal failure patients are needed to assess whether these findings predict future clinical outcomes.</description><identifier>ISSN: 0253-5068</identifier><identifier>EISSN: 1421-9735</identifier><identifier>DOI: 10.1159/000112465</identifier><identifier>PMID: 18075247</identifier><identifier>CODEN: BLPUDO</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Apolipoproteins B - blood ; Biological and medical sciences ; Biomarkers - blood ; Cardiovascular Diseases - etiology ; Emergency and intensive care: renal failure. Dialysis management ; Female ; Humans ; Intensive care medicine ; Kidney Failure, Chronic - blood ; Kidney Failure, Chronic - complications ; Kidney Failure, Chronic - therapy ; Lipoproteins, LDL - blood ; Male ; Medical sciences ; Middle Aged ; Original Paper ; Renal Dialysis - adverse effects</subject><ispartof>Blood purification, 2007-01, Vol.25 (5-6), p.457-465</ispartof><rights>2007 S. Karger AG, Basel</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c334t-99e6db71cf297a4e76c3d959dbec48d0962e2eadbcbafe9d40ee542cc043005f3</citedby><cites>FETCH-LOGICAL-c334t-99e6db71cf297a4e76c3d959dbec48d0962e2eadbcbafe9d40ee542cc043005f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20010863$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18075247$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bossola, Maurizio</creatorcontrib><creatorcontrib>Tazza, Luigi</creatorcontrib><creatorcontrib>Merki, Esther</creatorcontrib><creatorcontrib>Giungi, Stefania</creatorcontrib><creatorcontrib>Luciani, Giovanna</creatorcontrib><creatorcontrib>Miller, Elizabeth R.</creatorcontrib><creatorcontrib>Lin, Edward B.</creatorcontrib><creatorcontrib>Tortorelli, Antonio</creatorcontrib><creatorcontrib>Tsimikas, Sotirios</creatorcontrib><title>Oxidized Low-Density Lipoprotein Biomarkers in Patients with End-Stage Renal Failure: Acute Effects of Hemodialysis</title><title>Blood purification</title><addtitle>Blood Purif</addtitle><description>Objective: To assess the effect of end-stage renal failure on oxidized low-density lipoprotein (OxLDL) biomarkers and the acute effects of hemodialysis. Oxidized phospholipids (OxPL) on apolipoprotein B-100 (apoB) particles (OxPL/apoB) have been associated with cardiovascular disease and new cardiovascular events. Patients with end-stage renal failure have increased oxidative stress and are at significantly increased risk of cardiovascular disease. Methods and Results: Fifty-two stable patients with end-stage renal failure undergoing chronic hemodialysis were included in the study. Pre and post hemodialysis blood samples were obtained for measurement of OxLDL biomarkers: oxidized phospholipids (OxPL) on apolipoprotein B-100 (apoB) particles (OxPL/apoB) measured by antibody E06, IgG and IgM autoantibody titers to copper-oxidized LDL (Cu-OxLDL) and malondialdehyde (MDA)-LDL, IgG and IgM apolipoprotein B-100-immune complexes (IC/apoB). Traditional laboratory variables as well as C-reactive protein (CRP) and lipoprotein(a) [Lp(a)] were also measured. For the baseline variables, the distribution of OxPL/apoB and Lp(a) were skewed to lower values, and a strong correlation was noted between OxPL/apoB and Lp(a) (r = 0.94, p < 0.0001). No major associations were noted between OxLDL biomarkers and age, gender or dialytic age. There were also no correlations between OxLDL biomarkers and traditional risk factors, CRP, body mass index, serum creatinine, hypertension or intravenous iron therapy. Following dialysis, there as a significant reduction in OxPL/apoB (–7.5%, p = 0.048) and triglyceride levels (–10.8%, p = 0.005). All other OxLDL biomarkers, CRP, total cholesterol, LDL-C, HDL-C and apoB-100 increased significantly (range 6.3–26.9%, p value range 0.005 to <0.0001). Total protein plasma levels increased 8.8% (p = 0.014 compared to predialysis) following dialysis, consistent with a hemoconcentration effect of hemodialysis. Conclusion: In end-stage renal failure patients undergoing hemodialysis, a reduction in OxPL/apoB levels was noted, despite the hemoconcentrating and strong pro-oxidant milieu of hemodialysis. Studies in larger populations of end-stage renal failure patients are needed to assess whether these findings predict future clinical outcomes.</description><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Apolipoproteins B - blood</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Cardiovascular Diseases - etiology</subject><subject>Emergency and intensive care: renal failure. Dialysis management</subject><subject>Female</subject><subject>Humans</subject><subject>Intensive care medicine</subject><subject>Kidney Failure, Chronic - blood</subject><subject>Kidney Failure, Chronic - complications</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Lipoproteins, LDL - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Original Paper</subject><subject>Renal Dialysis - adverse effects</subject><issn>0253-5068</issn><issn>1421-9735</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0MtrGzEQBnBRUmon7SH3EHRpIIdN9Nxd5ZaH0wQMLn2cF600StWsd11JS-L-9ZGxcU7DwI9vmA-hY0ouKJXqkhBCKROl_ICmVDBaqIrLAzQlTPJCkrKeoMMY_2aVjfqEJrQmlWSimqK4ePXW_weL58NLcQd99GmN5341rMKQwPf4xg9LHZ4hRJy37zp56FPELz79wbPeFj-TfgL8A3rd4XvtuzHAFb42YwI8cw5MtoPDD7AcrNfdOvr4GX10uovwZTeP0O_72a_bh2K--PZ4ez0vDOciFUpBaduKGsdUpQVUpeFWSWVbMKK2RJUMGGjbmlY7UFYQACmYMURwQqTjR-hsm5tf-TdCTM3SRwNdp3sYxthUhNRc1DzD8y00YYgxgGtWween1w0lzabhZt9wtqe70LFdgn2Xu0oz-LoDOhrduaB74-PesZxE6nJz9GTrnnV4gvAetL3zBnuLjSg</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Bossola, Maurizio</creator><creator>Tazza, Luigi</creator><creator>Merki, Esther</creator><creator>Giungi, Stefania</creator><creator>Luciani, Giovanna</creator><creator>Miller, Elizabeth R.</creator><creator>Lin, Edward B.</creator><creator>Tortorelli, Antonio</creator><creator>Tsimikas, Sotirios</creator><general>Karger</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070101</creationdate><title>Oxidized Low-Density Lipoprotein Biomarkers in Patients with End-Stage Renal Failure: Acute Effects of Hemodialysis</title><author>Bossola, Maurizio ; Tazza, Luigi ; Merki, Esther ; Giungi, Stefania ; Luciani, Giovanna ; Miller, Elizabeth R. ; Lin, Edward B. ; Tortorelli, Antonio ; Tsimikas, Sotirios</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c334t-99e6db71cf297a4e76c3d959dbec48d0962e2eadbcbafe9d40ee542cc043005f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Apolipoproteins B - blood</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Cardiovascular Diseases - etiology</topic><topic>Emergency and intensive care: renal failure. Dialysis management</topic><topic>Female</topic><topic>Humans</topic><topic>Intensive care medicine</topic><topic>Kidney Failure, Chronic - blood</topic><topic>Kidney Failure, Chronic - complications</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Lipoproteins, LDL - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Original Paper</topic><topic>Renal Dialysis - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bossola, Maurizio</creatorcontrib><creatorcontrib>Tazza, Luigi</creatorcontrib><creatorcontrib>Merki, Esther</creatorcontrib><creatorcontrib>Giungi, Stefania</creatorcontrib><creatorcontrib>Luciani, Giovanna</creatorcontrib><creatorcontrib>Miller, Elizabeth R.</creatorcontrib><creatorcontrib>Lin, Edward B.</creatorcontrib><creatorcontrib>Tortorelli, Antonio</creatorcontrib><creatorcontrib>Tsimikas, Sotirios</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood purification</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bossola, Maurizio</au><au>Tazza, Luigi</au><au>Merki, Esther</au><au>Giungi, Stefania</au><au>Luciani, Giovanna</au><au>Miller, Elizabeth R.</au><au>Lin, Edward B.</au><au>Tortorelli, Antonio</au><au>Tsimikas, Sotirios</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oxidized Low-Density Lipoprotein Biomarkers in Patients with End-Stage Renal Failure: Acute Effects of Hemodialysis</atitle><jtitle>Blood purification</jtitle><addtitle>Blood Purif</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>25</volume><issue>5-6</issue><spage>457</spage><epage>465</epage><pages>457-465</pages><issn>0253-5068</issn><eissn>1421-9735</eissn><coden>BLPUDO</coden><abstract>Objective: To assess the effect of end-stage renal failure on oxidized low-density lipoprotein (OxLDL) biomarkers and the acute effects of hemodialysis. Oxidized phospholipids (OxPL) on apolipoprotein B-100 (apoB) particles (OxPL/apoB) have been associated with cardiovascular disease and new cardiovascular events. Patients with end-stage renal failure have increased oxidative stress and are at significantly increased risk of cardiovascular disease. Methods and Results: Fifty-two stable patients with end-stage renal failure undergoing chronic hemodialysis were included in the study. Pre and post hemodialysis blood samples were obtained for measurement of OxLDL biomarkers: oxidized phospholipids (OxPL) on apolipoprotein B-100 (apoB) particles (OxPL/apoB) measured by antibody E06, IgG and IgM autoantibody titers to copper-oxidized LDL (Cu-OxLDL) and malondialdehyde (MDA)-LDL, IgG and IgM apolipoprotein B-100-immune complexes (IC/apoB). Traditional laboratory variables as well as C-reactive protein (CRP) and lipoprotein(a) [Lp(a)] were also measured. For the baseline variables, the distribution of OxPL/apoB and Lp(a) were skewed to lower values, and a strong correlation was noted between OxPL/apoB and Lp(a) (r = 0.94, p < 0.0001). No major associations were noted between OxLDL biomarkers and age, gender or dialytic age. There were also no correlations between OxLDL biomarkers and traditional risk factors, CRP, body mass index, serum creatinine, hypertension or intravenous iron therapy. Following dialysis, there as a significant reduction in OxPL/apoB (–7.5%, p = 0.048) and triglyceride levels (–10.8%, p = 0.005). All other OxLDL biomarkers, CRP, total cholesterol, LDL-C, HDL-C and apoB-100 increased significantly (range 6.3–26.9%, p value range 0.005 to <0.0001). Total protein plasma levels increased 8.8% (p = 0.014 compared to predialysis) following dialysis, consistent with a hemoconcentration effect of hemodialysis. Conclusion: In end-stage renal failure patients undergoing hemodialysis, a reduction in OxPL/apoB levels was noted, despite the hemoconcentrating and strong pro-oxidant milieu of hemodialysis. Studies in larger populations of end-stage renal failure patients are needed to assess whether these findings predict future clinical outcomes.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>18075247</pmid><doi>10.1159/000112465</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0253-5068 |
ispartof | Blood purification, 2007-01, Vol.25 (5-6), p.457-465 |
issn | 0253-5068 1421-9735 |
language | eng |
recordid | cdi_crossref_primary_10_1159_000112465 |
source | MEDLINE; Karger Journals Complete |
subjects | Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Apolipoproteins B - blood Biological and medical sciences Biomarkers - blood Cardiovascular Diseases - etiology Emergency and intensive care: renal failure. Dialysis management Female Humans Intensive care medicine Kidney Failure, Chronic - blood Kidney Failure, Chronic - complications Kidney Failure, Chronic - therapy Lipoproteins, LDL - blood Male Medical sciences Middle Aged Original Paper Renal Dialysis - adverse effects |
title | Oxidized Low-Density Lipoprotein Biomarkers in Patients with End-Stage Renal Failure: Acute Effects of Hemodialysis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T04%3A51%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oxidized%20Low-Density%20Lipoprotein%20Biomarkers%20in%20Patients%20with%20End-Stage%20Renal%20Failure:%20Acute%20Effects%20of%20Hemodialysis&rft.jtitle=Blood%20purification&rft.au=Bossola,%20Maurizio&rft.date=2007-01-01&rft.volume=25&rft.issue=5-6&rft.spage=457&rft.epage=465&rft.pages=457-465&rft.issn=0253-5068&rft.eissn=1421-9735&rft.coden=BLPUDO&rft_id=info:doi/10.1159/000112465&rft_dat=%3Cproquest_cross%3E70083483%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70083483&rft_id=info:pmid/18075247&rfr_iscdi=true |